Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448026 | 0.84 | MAOB (0.61) | PARP15MAOBKDM4ENPC1GAA | |
| SCHEMBL11283190 | 0.83 | MAOB (0.59) | PARP15MAOBKDM4ENPC1GAA | |
| SCHEMBL10797158 | 0.83 | MAOB (0.72) | PARP15MAOBKDM4ENPC1GAA | |
| SCHEMBL22498647 | 0.82 | LRRK2 (0.54) | KDM4ENPC1GAARAB9ASMN1; SMN2 | |
| SCHEMBL12111167 | 0.82 | MAOB (0.59) | PARP15MAOBKDM4ENPC1GAA | |
| SCHEMBL11280271 | 0.82 | MAOB (0.58) | PARP15MAOBKDM4ENPC1GAA | |
| SCHEMBL10373885 | 0.82 | MAOB (0.58) | PARP15MAOBKDM4ENPC1GAA | |
| SCHEMBL6140955 | 0.82 | PARP15 (0.75) | PARP15MAOBKDM4ENPC1GAA | |
| SCHEMBL3191667 | 0.82 | MAOB (0.58) | PARP15MAOBKDM4ENPC1GAA | |
| SCHEMBL30343022 | 0.82 | MAOB (0.58) | PARP15MAOBKDM4ENPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570117-B2 | Phenylimidazole compound | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570117-B2 | Phenylimidazole compound | LPL, PNLIP, LIPC | PARP15 2586/4885MAOB 618/4885KDM4E 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.